Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024. In the quarter to June 2026, revenue fell 70.1%, EPS grew 56.8% and free cash flow grew 75.7%, each against the same quarter a year earlier.
Follow AVTX
Avalo Therapeutics, Inc. (AVTX) EV/Sales
As of 16 October 2026, Avalo Therapeutics, Inc. (AVTX) trades at a EV/Sales of 82.3×. Over the past ten years it has ranged from −1,784× (December 2019) to 414× (August 2026); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 126× | — |
| FY2024 | −72.3× | — |
| FY2023 | 3.4× | 26.22% |
| FY2022 | 2.7× | (90.37%) |
| FY2021 | 27.9× | 15.17% |
| FY2020 | 24.2× | (30.97%) |
| FY2019 | 35.1× | 108.67% |
| FY2018 | 16.8× | 677.99% |
| FY2017 | 2.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | −72.3× | — |
| Sep 2024 | −10.4× | — |
| Dec 2023 | 3.4× | 11.22% |
| Sep 2023 | 3.0× | 410.01% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | 2.2× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| SLDB Solid Biosciences Inc. compare | 37.0× |
| AVTX Avalo Therapeutics, Inc. | 82.3× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)